Toggle navigation EN

Publikationen 2008

  1. Winnenburg R, Urban M, Beachem A, Baldwin TK, Holland S, Lindeberg M, Hansen H, Rawlings C, Hammond-Kosack KE, and Köhler J. PHI-base update: Additions to the Pathogen Host Interaction Database. Nucleic Acids Research, Jan. 2008, (in press)
  2. Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, and Lötsch J. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther 2008 Apr;83(4):577-88
  3. Coste O, Pierre S, Marian C, Brenneis C, Angioni C, Schmidt H, Popp L, Geisslinger G, and Scholich K. Antinociceptive activity of the S1P-receptor agonist FTY720. J Cell Mol Med 2008 12:995-1004
  4. Niederberger E and Geisslinger G. Proteomics in pain research. Anesthesiology 2008 Feb;108(2):314-23
  5. Janssen A, Schiffmann S, Birod K, Maier TJ, Wobst I, Geisslinger G, and Grösch S. p53 is important for the anti-proliferative effect of ibuprofen in colon carcinoma cells. Biochem Biophys Res Commun 2007 Nov 21 [Epub ahead of print]
  6. Scholz J, Abele A, Marian C, Häussler A, Herbert AT, Woolf CJ, and Tegeder I. Low-dose methotrexate reduces peripheral nerve injury-evoked spinal microglial activation and neuropathic pain behavior in rats. Pain 2008 (accepted)
  7. Graff J, von Hentig N, Kuczka K, Angioni C, Gute P, Klauke S, Babacan E, and Harder S. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. J Antimicrobial Chemotherapy 2008 Feb;61(2):394-9
  8. Neddermeyer TJ, Flühr K, and Lötsch J. Principle components analysis of pain thresholds to thermal, electrical and mechanical stimuli suggests a predominant common source of variance. Pain Aug 31;138(2):286-91
  9. Antoniades C, Shirodaria C, Van Assche T, Cunnington C, Tegeder I, Lötsch J, Guzik TJ, Leeson P, Diesch J, Tousoulis D, Stefanadis C, Costigan M, Woolf CJ, Alp NJ, and Channon KM: GCH-1 haplotype determines vascular and plasma biopterin availability in coronary artery disease: Effects on vascular superoxide production and endothelial function. J Am Coll Cardiol 2008 Jul 8;52(2):158-65
  10. Mills C, Makwana M, Wallace A, Benn S, Schmidt H, Tegeder I, Costigan M, Coggeshall R, Brown G, Raivich G, and Woolf C. Ro5-4864 promotes neonatal motor neuron survival and nerve regeneration in adult rats. Eur J Neuroscience 2008 (accepted)
  11. Degousee N, Fazel S, Angoulvant D, Stefanski E, Pawelzik SC, Korotkova M, Arab S, Liu P, Lindsay TF, Zhuo S, Butany J, Li RK, Audoly L, Schmidt R, Angioni C, Geisslinger G, Jakobsson PJ, and Rubin RB. Microsomal Prostaglandin E2 Synthase-1 Deletion leads to Adverse Left Ventricular Remodeling After Myocardial Infarction. Circulation 2008 (accepted)
  12. Weber M, Burian M, Dragutinovic I, Moellmann H, Nef H, Elsaesser A, Mitrovic V, Hamm C, and Geisslinger G.Genetic polymorphism of the Type A Human Natriuretic Peptide Receptor (NPR-A) Gene contributes to the interindividual variability in the BNP system. Eur J Heart Failure 2008 (accepted)
  13. Lötsch J, Reichmann H, and Hummel T. Different odor tests contribute differently to the evaluation of olfactory loss. Chem Senses 2008, 33: 17-21
  14. Oertel B, Lötsch J. Genetic mutations which prevent pain: implications for future pain medication. Pharmacogenomics 2008 Feb;9(2):179-94.
  15. Tegeder I , Adolph J, Schmidt H, Woolf CJ, Geisslinger G, and Lötsch J. Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. Eur J Pain 2008 Nov;12(8):1069-77
  16. Schmidtko A, Gao W, Sausbier M, Rauhmeier I, Sausbier U, Niederberger E, Scholich K, Huber A, Neuhuber W, Allescher H, Hofmann F, Tegeder I, Ruth P, and Geisslinger G. Cysteine-rich protein 2, a novel downstream effector of cGMP/cGMP-dependent protein kinase I mediated persistent inflammatory pain. J Neurosci 2008 Feb 6;28(6):1320-1330
  17. von Hentig N, Kaykhin P, Stephan C, Babacan E, Stürmer M, Staszewski S, and Lötsch J. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double HIV-protease inhibitor salvage regimen. Antimicrob Agents Chemother. 2008 Jun;52(6):2273-5
  18. von Hentig N. Plasmaspiegelmessung antiretroviraler Arzneimittel der HIV Therapie. Dtsch Med Wochenschr. 2008 Feb 133(5):191-95 
  19. Klarmann D, Martinez Saguer I, Funk, MB, Knofler R, von Hentig N, Heller C, Kreuz W. Immune tolerance induction with myophenolate-mofetil in two children with haemophilia B and inhibitor. Haemophilia 2008 Jan. 14(1):44-49. 
  20. von Hentig N, Babacan E, Stephan C, Lennemann T, Knecht G, Carlebach A, Harder S, Staszewski S, and Haberl A. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008 Sep;62(3):579-82
  21. von Hentig N. Atazanavir/ritonavir: Review of its use in HIV therapy. Drugs Today 2008  Feb;44(2):103-133
  22. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G and Grösch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008 (in press)
  23. Schiefelbein D, Goren I, Fisslthaler B, Schmidt H, Geisslinger G, Pfeilschifter J, Frank S. Biphasic Regulation of HMG-CoA Reductase Expression and Activity during Wound Healing and Its Functional Role in the Control of Keratinocyte Angiogenic and Proliferative Responses. J Biol Chem 2008 May 30;283(22):15479-90
  24. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): Relation to FXa-activity and influence of assay modifications. Thromb Res 2008 Jun 20. [Epub ahead of print]
  25. Kuczka K, Harder S, Picard-Willems B, Warnke A, Donath F, Bianchini P, Parma B, Blume H. Biomarkers and coagulation tests for assessing biosimilarity of a generic low molecular weight heparin: results of astudy in healthy subjects with enoxaparin. J Clin Pharm Aug 20, 2008  [Epub ahead of print]
  26. Schmidtko A, Luo C, Gao W, Geisslinger G, Kuner R, Tegeder I. Genetic deletion of synapsin II reduces neuropathic pain due to reduced glutamate but increased GABA in the spinal cord dorsal horn. Pain (2008) (in press)
  27. Schmidtko A, Gao W, König P, Heine S, Motterlini R, Ruth P, Schlossmann J, Koesling D, Niederberger E, Tegeder I, Friebe A, and Geisslinger G. cGMP produced by NO-sensitive guanylyl cyclase essentially contributes to inflammatory and neuropathic pain by using targets different from cGMP-dependent protein kinase I. J Neurosci 2008 (accepted)
  28. Schiefelbein D, Seitz O, Goren I, Dibmann JP, Schmidt H, Bachmann M, Sader R, Geisslinger G, Pfeilschifter J, Frank S. Keratinocyte-derived VEGF biosynthesis represents a pleiotropic side effect of PPAR{gamma} agonist troglitazone but not rosiglitazone and involves activation of p38 MAPK: implications for diabetes-impaired skin repair. Mol Pharmacol 2008 Jul 3. [Epub ahead of print]
  29. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, Metzner J, Grösch S, Pergola C, Steinhilber D, Werz O, and Geisslinger G. Celecoxib inhibits 5-lipoxygenase. Biochemical Pharmacology 2008 (in press)
  30. von Hentig N, Förster AK, Kuczka K, Klinkhardt U, Klauke S, Gute P, Staszewski S, Harder S, Graff J. Platelet-leukocyte adhesion markers before and after the intiation of antiretroviral therapy with HIV protease inhibitors. J Antimicrob Chemother 2008 Aug 27 [Epub ahead of print]
  31. Pierre S, Maeurer C, Coste O, Becker W, Pfenninger A, Schmidtko A, Holland S, Wittpoth C, Geisslinger G, Scholich K. Toponomic analysis of PAM-associated protein interactions at synapses during spinal nociceptive processing. Mol. Cell Proteomics 2008, 7:2475-85
  32. Walenga JM, Drenth AF, Mayuga M, Hoppensteadt SA, Prechel M, Harder S, Watanabe H, Osakabe M, Breddin HK. Transition from Argatroban to Oral Anticoagulation with Phenprocoumon or Acenocoumarol: Effect on Coagulation Factor Testing. Clinical and Applied Thrombosis/Hemostasis  2008 Jul;14(3):325-31    
  33. Harder S, Koster A, Klinkhardt U. The Direct Thrombin Inhibitor Argatroban: A Review of its Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationship. Semin Thromb Hemost 2008; 34: 75 -80
  34. Wobst I, Schiffmann S, Birod K, Maier TJ, Schmidt R, Angioni C, Geisslinger G, Grösch S. Dimethylcelecoxib inhibits prostaglandin E2 production. Biochem Pharmacol 2008 Jul 1;76(1):62-9.
  35. Brenneis C, Coste O, Schmidt R, Angioni C, Popp L, Nusing RM, Becker W, Scholich K, Geisslinger G. Consequences of altered eicosanoid patterns for nociceptive processing in mPGES-1-deficient mice. J Cell Mol Med. 2008 Apr;12(2):639-48.
  36. Coste O, Brenneis C, Linke B, Pierre S, Maeurer C, Becker W, Schmidt H, Gao W, Geisslinger G, Scholich K. Sphingosine-1-phosphate modulates spinal nociceptive processing. J Biol Chem. 2008  Nov 21;283(47):32442-51
  37. Schiffmann S, Maier TJ, Wobst I, Janssen A, Corban-Wilhelm H, Angioni C, Geisslinger G and Grösch S. The anti-proliferative potency of celecoxib is not a class effect of coxibs. Biochem Pharmacol 2008 Jul
    15; 76 (2): 179-87
  38. Maier TJ, Tausch L, Hoernig M, Coste O, Schmidt R, Angioni C, Metzner J, Grösch S, Pergola C, Steinhilber D, Werz O, and Geisslinger G. Celecoxib inhibits 5-lipoxygenase. Biochemical Pharmacology 2008 Oct 1; 76 (7); 862-72
  39. Ruckhäberle E, Rody A, Engels K, Gaetje R, von Minckwitz G, Schiffmann S, Grösch S, Geisslinger G,Holtrich U, Karn T, Kaufmann M. Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat 2008 Nov;112(1):41-52
  40. Niederberger E, Kühlein H, Geisslinger G. Update on the pathobiology of neuropathic pain. Expert Rev Proteomics 2008 Dec;5(6):799-818
  41. Niederberger E, Geisslinger G. The IKK-NF-kappaB pathway: a source for novel molecular drug targets in pain therapy? FASEB J. 2008 Oct;22(10):3432-42.